

## MODULE 6.7

## Hexosamine Pathway

The hexosamine pathway is another downstream consequence of oxidative stress. As described in Module 6.4, Brownlee proposed oxidative stress as a unifying mechanism that links all the damaging biochemical pathways induced in diabetic retinopathy (DR) by hyperglycemia.<sup>1,2</sup> That theory holds that overproduction of reactive oxygen species by mitochondria is the single upstream event that activates four separate metabolic pathways: (1) increased intracellular production of advanced glycation end products (AGEs), activation of protein kinase C (PKC), increased flux in the polyol pathway, and overactivation of the hexosamine pathway.<sup>3</sup>


When glucose is elevated in a cell, most of it is metabolized by glycolysis: first to glucose 6-phosphate, then to fructose 6-phosphate, and then on through the pathway. In hyperglycemia-induced oxidative stress, the flux of fructose 6-phosphate into the hexosamine pathway is increased, diverting it from the glycolytic pathway. Here it is converted

by the enzyme glutamine: fructose 6-phosphate amidotransferase (GFAT) into glucosamine 6-phosphate, which is subsequently converted to uridine diphosphate-N-acetylglucosamine (UDPGlcNAc), a hexosamine.<sup>1,3</sup>

UDPGlcNAc then binds to specific serine and threonine residues in transcription factors, leading to pathologic changes in gene expression, such as increases in transcription of transforming growth factor (TGF)  $\alpha$  and TGF $\beta$ . Increased activation of transcription factor Sp1 through the hexosamine pathway, induced by hyperglycemia, has been shown to lead to the activation of plasminogen activator inhibitor-1 (PAI-1).<sup>1,3</sup> PAI-1 is upregulated by both the PKC and hexosamine pathways, again illustrating how these four separate pathways are interconnected in diabetes.<sup>3</sup>

## Hexosamine Pathway in DME

## HYPERGLYCEMIA INCREASES FLUX OF HEXOSAMINE PATHWAY



## References

1. Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. *Diabetes*. 2005;54:1615-1625.
2. Tarr JM, Kaul K, Chopra M, Kohner EM, Chibber R. Pathophysiology of diabetic retinopathy. *ISRN Ophthalmol*. 2013;2013:343560.
3. Wu Y, Tang L, Chen B. Oxidative stress: implications for the development of diabetic retinopathy and antioxidant therapeutic perspectives. *Oxid Med Cell Longev*. 2014;2014:752387.